Henning Schade M.D.

Blood and Marrow Transplant Physician

Colorado Blood Cancer Institute

1721 East 19th Avenue, Suite #300, Denver, CO 80218

720-754-4800 (office) 866-341-6984 (fax)

Henning.Schade@HealthONEcares.com

www.coloradoblood.com

Education:

2008-current​​​​USMLE Step 2 October 2008

USMLE Step 1 May 2009

USMLE Step 2CK August 2010

USMLE Step 3 March 2012

2001 – 2006​Medical Studies at Christian-Albrechts-Universität zu Kiel, Germany

1st Board Exam September 2002

2nd Board Exam September 2004

3rd Board Exam May 2006

1999 –2001​Preclinical Medical Studies 

Universität Göttingen, Germany

​​Preclinical Board Exam May 2001

1995-1998​​​​Nursing School Altperlach/ Munich

Nursing School Kassel Clinic

Nursing Board Exam September 1998

1986-1994​​​​High School Homberg/ Efze, Germany

Professional Board Certifications / Licenses:

2014 ​​​​​Internal Medicine, Board Certified, American Board of 

Internal Medicine

2016​​​​​Medical Oncology, Board Certified, American Board of 

Internal Medicine

Colorado Medical License​​#0056526​

Professional Experience:

1994-1995 Civil Service Caritas Kassel, Germany

2006-2010​Internal Medicine residency at University of Kiel, Germany, 

2010-2011​Observership, BMT at Medical University of South Carolina

2011-2014​Resident Physician, Internal Medicine residency at Medical University of South Carolina

2014- 2016​Hematology/Oncology Fellowship at University of Colorado

2016-2017 ​​​​Fellowship – BMT, Colorado Blood Cancer Institute

2017- Present​​​​Attending Physician-Colorado Blood Cancer Institute

Hospital Affiliation:

HCA HealthONE Presbyterian/St. Luke’s Medical Center, 1719 E. 19th Avenue, Denver, Colorado 80218

Languages:

Fluent in written and spoken German and English.

Research – USA

2023-current​PI IgM 2644 phase 1 trial for relapsed/refractory Myeloma

2023-current​PI Phase 2 Outpatient Teclistamab study 

2023-current​PI Phase Ib study with Isatuximab, high dose weekly Carfilzomib and Dexamethasone

2021 – current​PI for phase IB study with Cevostamab for relapsed/refractory Myeloma

2020 – 2021​PI  for DREAMM 8 study for relapsed/refractory myeloma

2020 – 2021​PI  for STOMP trial for relapsed/refractory myeloma

2020 – current​PI of Phase  I trial: HPN217, a half-life extended TriTAC targeting BCMA for treatment of relapsed/refractory multiple myeloma

2018-2020​PI of Phase I Trial: BMT 30 Graft-Versus-Tumor Augmentation with Nivolumab Consolidation for High-Risk Patients with MDS and AML after Allogeneic Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide

PI Phase II Trial:

​Phase II Single Arm Study of Nivolumab as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma at Risk of Relapse or Progression 

2015-2016​Colorado Blood Cancer Institute with University of Colorado, translational research with Drs. Palmer, Verneris and McSweeney:  T and NK cell exhaustion following autologous and allogeneic stem cell transplantation.

2014-2016​University of Colorado, clinical research with Dr. Pollyea, Jumping translocations, double minutes and homogeneously staining regions; uncommon oncogene amplifications in myeloid malignancies 

2012-2014​​​​MUSC, Laboratory research under Dr..Kang’s mentorship: 

1.PIM-kinase expression in multiple myeloma cell lines

2.Sphingolipid metabolism in multiple myeloma cell lines

2011-2014​MUSC, Clinical research with Dr..Costa with main topic on stem cell mobilizationstrategies:

1.Mobilization of hematopoietic stem cells in patients 

with multiple myeloma utilizing growth factor combined with plerixafor

2. Assessment of the residual CD34+ count in the peripheral blood at the end of standard three blood volumes leukapheresis and potential for higher CD34+ yield with large volume leukapheresis (LVL) in patients undergoing autologous hematopoietic stem cell collection

Research -Germany

2009-2013​University of Kiel, clinical research with Prof..Humpe:  Second allogeneic stem cell transplantation in hematologic malignancies (doctoral thesis)

2007-2008​University of Kiel, clinical research with Prof. Repp: Treatment of relapsed or refractory mature T/NK- cell NHL with BEAM-alemtuzumab conditioning followed by allogeneic stem cell transplantation

2002​University of Kiel, Quality of life after laser-based surgery for pharynx and larynx carcinomas, clinical research with Prof. Maune

PUBLICATIONS

Poster/Abstracts

2023 ​Sumit Madan, MD, Caitlin L. Costello, MD, Brea Lipe, MD, Andrew J. Cowan, MD, Eva Medvedova, MD10*, Jens Hillengass, MD, PhD11, P. Leif Bergsagel, MD, Xavier Leleu, MD, Cyrille Touzeau, MD, PhD14*, Daniel Morillo, MD15*, Albert Oriol16*, Raya Mawad, MD17, Henning Schade, MD18*, Salomon Manier, MD, PhD19, Yifah Yaron, MD, PhD, Banmeet Anand, PhD and Al-Ola Abdallah, MD 1012 Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)​

P-047 Trial in progress: an open-label, multicenter, phase 1 study for IGM-2644 in participants with relapsed and/or refractory multiple myeloma, Roel Funke, Henning Schade et al, Clinical Lymphoma, Myeloma & Leukemia, 2023-09-01, Volume 23, Pages S60-S61,

2020​Henning Schade, MD, Sumit Madan, MD, Eva Medvedova, MD, Rajneesh Nath, MD,Lisa Knapp, Bryan Lemon, PhD and Liping Laura Sun, PhDHPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma

2016​Andrew Thomas Johnson, Zohra Nooruddin, Gentry Teng King, Henning Helmut Schade, Manali K. Kamdar, Brad M. HaverkosSingle institution retrospective review of patients with primary CNS lymphoma (PCNSL), ASCO 2016

2014​Henning Schade, Yubin Kang, Chhabra Saurabh, Robert K  Edwards, Cindy Kramer, Mollie Schneider, Amanda Littleton, Katie B Shoptaw, Luciano J Costa

Similar Dynamics Of Intra Apheresis Autologous CD34+ Recruitment and Collection Efficiency In Patients Undergoing Mobilization With Or Without Plerixafor, Poster at MUSC research day 2014

2013​Henning Schade, Yubin Kang, Chhabra Saurabh, Robert K  Edwards, Cindy Kramer, Mollie Schneider, Amanda Littleton, Katie B Shoptaw, Luciano J Costa

Similar Dynamics Of Intra Apheresis Autologous CD34+ Recruitment and Collection Efficiency In Patients Undergoing Mobilization With Or Without Plerixafor, Blood November 15, 2013 vol. 122 no. 21 904

2013​Jagadish Kummetha Vetenka, Ningfei An, Henning Schade, Luciano Costa, Charles Smith and Yubin Kang

Sphingolipids as a novel target for thetreatment of multiple myeloma, poster at MUSC research day 2013

2012​H Schade, A Humpe: Second allogeneic stem cell transplantation in hematological malignancies; a single center retrospective analysis, Journal of Investigative Medicine, Jan 2012, Vol 60, Number 1, abstract 357.

2010​H. Schade, A. Humpe, A. Guenther, A. Schrauder, T. Valerius, M.Gramatzki: Secondallogeneic stem cell transplantation for relapsed leukaemias: a single-centreoutcome study, EBMT 2010 poster and abstract

2008 ​R. Repp, A. Günther, H. Schade, A. Humpe, B. Gahn, M. Nickelsen, A. Claviez: BEAM-alemtuzumab followed by allogeneic SCT for the treatment of relapsed or refractory T-NHL, poster and abstract presentation at ASCO 2008

2008​Gramatzki, M., Schade, H., Schrauder, A., Humpe, A., Repp, R.: A successful treatment strategy for patients with T-NHL: Allogeneic Transplantation after Beam-Alemtuzumab Conditioning, Biology of Blood and Marrow Transplantation,Volume 14, Issue 2, Supplement , Page 66

Günther A, Schade H, Humpe A, GahnB, Claviez A, Schrauder A et al.: BEAM-alemtuzumab followed by allogeneic SCT is a feasible and highly efficient treatment strategy in relapsed or refractory T-NHL. Bone Marrow Transplant 2008; 41 (S1): S244.

2007 ​

R. Repp, H. Schade, A. Günther, A. Humpe, B. Gahn, A. Claviez, A. Schrauder, M. Gramatzki: Successful treatment of relapsed or refractory mature T/NK- cell NHL with BEAM-alemtuzumab conditioning followed by allogeneic stem cell transplantation, DGHO 2007 poster and abstract

Book chapters

2012​Henning Schade, Luciano Costa

​Mobilization of hematopoietic stem cells in patients 

with multiple myeloma utilizing growth factor combined with plerixafor

Chapter 26, Page 299-307

“Stem cells and cancer stem cells Volume 6” by M.A.Hayat, Springer

Peer reviewed publications

1. Emma Golden, Sara Ingram, Henning Schade, Jeffrey Matous and Tara K Gregory. Novel Therapies in BCMA-exposed Relapsed/Refractory Multiple Myeloma: The Anti-BCMA Therapy-refractory Patient. touchREVIEWS in Oncology & Haematology. 2022;18(1):59–65

2. Gregory T.K. , Schade, H. , Berdeja J.G. Latest developments in cellular therapy for multiple myeloma, Oncology & Hematology Review (US). 2020;16(2):111-8

3. Schade H, Davis L, Kabos P, Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer, Oncology (Williston Park). 2016 Nov 15;30(11). pii: 219808.

4. Henning Schade, Sharon Sen, C. Preston Neff, Brian M. Freed, Jonathan A. Gutman and Brent E. Palmer PD-1 expression on CD4+ T cells predicts mortality following allogeneic stem cell transplantation, BBMT August 09,2016

5. Batley KE, Schade H, Purcell WT, Crawford ED, Subacute headache in a patient with metastatic gastric cancer, Oncology (Williston Park). 2015 May;29(5):390, C3

6. Schade, Henning, Chhabra, Saurabh, Kang, Yubin , Stuart,  Robert, Hogan, Kathy, Kramer, Cindy, Butcher, Coleen, Littleton, Amanda, Schneider, Molly, Budisavljevic, Milos, Costa, Luciano Similar Dynamics Of Intra Apheresis Autologous CD34+ Recruitment and Collection Efficiency In Patients Undergoing Mobilization With Or Without Plerixafor, Transfusion, published online June 2014

7. Henning Schade, Zweite allogene Stammzelltransplantationbei rezidivierten malignen hämatologischen Erkrankungen: Eine retrospektive monozentrische Studie. Doctoral thesis, Library University of Kiel

8. Woodrow J Coker, Ashley Jeter, Henning Schade and YubinKang, Plasma cell disorders in HIV-infected patients and molecular mechanisms, Biomarker Research, February 2013